iX Biopharma (SGX:42C) COGS-to-Revenue : 0.78 (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma COGS-to-Revenue?

iX Biopharma's Cost of Goods Sold for the six months ended in Dec. 2024 was S$2.88 Mil. Its Revenue for the six months ended in Dec. 2024 was S$3.71 Mil.

iX Biopharma's COGS to Revenue for the six months ended in Dec. 2024 was 0.78.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. iX Biopharma's Gross Margin % for the six months ended in Dec. 2024 was 22.33%.

iX Biopharma COGS-to-Revenue Historical Data

The historical data trend for iX Biopharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma COGS-to-Revenue Chart

iX Biopharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

COGS-to-Revenue

Get a 7-Day Free Trial

1.60

1.22

0.15

0.61

0.82

iX Biopharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
COGS-to-Revenue	Get a 7-Day Free Trial															0.65	0.58	0.78	0.86	0.78

iX Biopharma COGS-to-Revenue Calculation

iX Biopharma's COGS to Revenue for the fiscal year that ended in Jun. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	4.911	/	5.959
	=	0.82

iX Biopharma's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2.884	/	3.713
	=	0.78

iX Biopharma (SGX:42C) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

iX Biopharma's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	2.884 / 3.713
	=	22.33 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

iX Biopharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of iX Biopharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma Headlines

No Headlines